Regulation FD Disclosure, Business/Financial Results (Form 8-K)

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2026, Acadia Pharmaceuticals, Inc. (the "Company") presented at the J.P. Morgan Healthcare Conference announcing, among other things, that it anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance. In connection with such presentation, the Company posted a corporate slide presentation in the "Investors" portion of its website at ir.acadia.com.

Item 7.01 Regulation FD Disclosure.

The disclosure set forth in Item 2.02 above is incorporated by reference into this Item 7.01.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.